BioPen operates in the $10 billion rapidly growing Point-of-Care (POC) market, which is a third of the current $29 billion global In-Vitro Diagnostic (IVD) market. Market trends which in recent years, focus on nearer-to-patient testing and decentralization of diagnostics, are now driving rapid ...
1586128335.jpg)